-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
Join hands with the big coffee, please look forward to an academic feast in the field of rheumatic immunity and skin immune diseases!
Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and highly disabling diseases involving improper or excessive immune responses, including rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and other diseases
。 Over the past two decades, there have been significant changes in the therapeutic drugs for IMIDs, from initial broad-spectrum immunomodulators to specific formulations to targeted drugs, which have had a significant impact
on the development of therapeutic strategies.
At present, the treatment strategy of rheumatic immunity and skin immune diseases has entered the era
of biological agents and targeted drugs.
For example, the emergence of bio-remission antirheumatic drugs (bDMARDs) and targeted synthetic anti-rheumatic drugs (tsDMARDs) has promoted the treatment strategy of RA from pain relief to standard treatment [1].
At the same time, the approval of a variety of biological agents has brought new options and new hopes for psoriasis, systemic lupus erythematosus and other diseases [2].
However, there is still an unmet clinical need
for rheumatic and cutaneous immune diseases.
In response to these challenges, it is necessary to have an in-depth discussion and look forward to the future development trends
in the field of skin immunity and rheumatic immune diseases.
RA, which focuses on the unmet need in rheumatic and cutaneous immune diseases, is a common disease among IMIDs, and its treatment strategy has changed from simple relief of joint swelling and pain to advocating early intensive therapy and standard treatment [1].
。 The evolution of RA treatment strategies is a good example of the phenomenon
of advancing medical development from unmet clinical needs in the treatment of rheumatic immune diseases.
However, in the current era of biologics and targeted drugs, there are other unmet needs of RA patients that require our attention
.
For example, when joint pain and injury are relieved, can the quality of life of RA patients be significantly improved? Are there other factors that affect quality of life that have been overlooked [3]? In addition, can patients with RA maintain remission rates after drug reduction [4]? Are there more reliable predictors? A more challenging question is – how to prevent rheumatoid arthritis? Has the current study found a precise target [5]?
There is also an unmet need
for patients with skin immune diseases such as psoriasis and systemic lupus erythematosus.
Patients with skin immune diseases often carry a heavy burden of disease, which comes from appearance, stigma, economic pressure, social barriers and other aspects [6].
Biologics have shown positive therapeutic effects in the treatment of these diseases, and access has also improved
.
However, how to comprehensively and effectively "reduce the burden" for patients with skin immune diseases still needs to be explored
.
"Focus on immunity, empower the future together", join hands to meet new challenges!
In this era of rheumatic immunity and skin immune disease treatment strategies into biologics and targeted drugs, Eli Lilly insists on the research and development and marketing of drugs in the field of immunity, and looks forward to the approved new immunotherapy drugs to better serve the clinical treatment in China and improve the lives of
patients.
A century of R&D accumulation has created the cornerstone
of Lilly's autoimmune research and development.
Eli Lilly Academy of Immunology hopes to grow
together with the Chinese immunization field.
In view of this, Eli Lilly Academy of Immunology will hold the third anniversary celebration meeting of "Focus on Immunization, Empower the Future" offline and online on November 20, 2022
.
The conference gathered well-known experts in the field of rheumatology and immunology and skin immunity at home and abroad, focusing on the field of rheumatic immunity and skin immune diseases, and deeply discussed the unmet clinical needs in the field of diseases and the prospect
of the development trend of the field.
Professor Paul Emery of the University of Leeds and Professor Diamant Thaci of the University of Lubeck in Germany will bring you the international cutting-edge information and latest research progress
in rheumatology and dermatology.
In this regard, we sincerely invite you to visit this conference and work together to build a splendid mountain and river of "focusing on immunity and empowering the future together"!
Click "Read Original" to book a live broadcast~
References:
[1] Smolen, J.
S.
et al.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Ann Rheum Dis ard-2022-223356 (2022) doi:10.
1136/ard-2022-223356.
[2] Nash, P.
et al.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Ann Rheum Dis 80, 71–87 (2021).
[3] Studenic, P.
, Radner, H.
, Smolen, J.
S.
& Aletaha, D.
Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity.
Arthritis Rheum 64, 2814–2823 (2012).
[4] Emery, P.
& Salmon, M.
Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 54, 944–947 (1995).
[5] Smolen, J.
S.
et al.
Rheumatoid arthritis.
Nat Rev Dis Primers 4, 18001 (2018).
[6] Hedemann, T.
L.
, Liu, X.
, Kang, C.
N.
& Husain, M.
I.
Associations between psoriasis and mental illness: an update for clinicians.
Gen Hosp Psychiatry 75, 30–37 (2022).
For medical professionals only, PP-MG-CN-2631
This article is only for providing scientific information to healthcare professionals and does not represent the position of
the platform.
